MNKD MannKind Corporation

1.56
+0.11  (+8%)
Previous Close 1.45
Open 1.52
Price To Book -1.21
Market Cap 248972214
Shares 159,597,573
Volume 3,544,783
Short Ratio
Av. Daily Volume 2,494,227

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes
Phase 1 trial completion announced June 7, 2018.
Treprostinil Technosphere
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
  2. MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
  3. MannKind Corporation Participating at Upcoming Conferences
  4. MannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019
  5. Weekly CFO Buys Highlight
  6. Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv — Emerging Consolidated Expectations, Analyst Ratings
  7. MNKD: Update From Our Meeting With MNKD at JPM
  8. Biotech Stocks on the Move
  9. How to spot risky biotech companies and six to avoid now
  10. MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day
  11. MannKind Corporation to Hold Investor Conference Call
  12. How Many MannKind Corporation (NASDAQ:MNKD) Shares Do Institutions Own?
  13. Why MannKind Stock Is Plunging Today
  14. Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and MannKind
  15. MannKind Announces Pricing of $40 Million Public Offering
  16. MannKind Announces Commencement of Public Offering
  17. MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target
  18. Biotech Stocks Beating the Market
  19. MannKind Appoints Christine Mundkur to its Board of Directors
  20. Analysts: Why United Therapeutics has had a streak of licensing deals